摘要
目的:观察芪归健脑方联合艾司西酞普兰治疗卒中后抑郁(PSD)合并认知功能障碍,对患者抑郁、认知功能,及血清淀粉样蛋白A(SAA)、β-淀粉样蛋白(Aβ)水平的影响。方法:124例PSD合并认知障碍患者随机分为两组各62例。对照组给予艾司西酞普兰治疗2个月,观察组给予芪归健脑方联合艾司西酞普兰治疗2个月。比较两组患者治疗前后抑郁评分、认知功能评分及SAA、Aβ水平的变化,观察两组药品不良反应发生情况。结果:治疗后,两组17项汉密尔顿抑郁量表(HAMD-17)评分,Zung抑郁自评量表(SDS)评分,以及SAA、Aβ水平均较前显著降低(P<0.05),蒙特利尔认知评估量表(MoCA)评分、简易智能精神状态检查量表(MMSE)评分则较前显著升高(P<0.05);且观察组各项指标均优于对照组(P<0.05)。两组不良反应发生率的差异无统计学意义(P>0.05)。结论:芪归健脑方联合艾司西酞普兰可抑制SAA、Aβ水平,改善PSD合并认知功能障碍患者抑郁症状,提高认知功能,效果优于单纯艾司西酞普兰治疗。
Objective:To observe the Effects of Qigui Jiannao prescription combined with citalopram in patients with post-stroke depression(PSD) complicated with cognitive dysfunction, and effects on depression, cognitive function and serum amyloid A(SAA)and β-amyloid(Aβ). Methods:124 patients with PSD combined with cognitive impairment were randomly divided into two groups according by random number table, 62 cases in each group. The control group was treated with citalopram for 2 months, while the observation group(62 cases) was treated with Qigui Jiannao prescription combined with citalopram for 2 months. The changes of depression scores, cognitive function scores, SAA and Aβ levels in 2 groups before and after treatment were compared, and the incidence of ADR in 2 groups was observed. Results:After treatment, the 17 items of Hamilton Depression Scale(HAMD-17) score, Zung Self-Rating Depression Scale(SDS) score, SAA and Aβ levels were significantly decreased in both groups(P<0.05), while the Montreal Cognitive Assessment Scale(MOCA) score and MMSE score were significantly increased(P<0.05). The indexes of observation group were better than control group(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion:Qigui Jiannao prescription combined with citalopram can inhibit the levels of SAA and Aβ, improve the depressive symptoms of PSD patients with cognitive dysfunction, improve the cognitive function, the effect is better than citalopram alone treatment.
作者
鲁跃
夏平
陶先明
胥明
胡铁弋
Lu Yue;Xia Ping;Tao Xianming;Xu Ming;Hu Tieyi(Sleep Psychosomatic Center,People’s Hospital of Dazu District,Chongqing 402360,China;Department of Traditional Chinese Medicine,People’s Hospital of Dazu District,Chongqing 402360,China;Department of Neurology,People’s Hospital of Dazu District,Chongqing 402360,China)
出处
《药物流行病学杂志》
CAS
2021年第5期301-304,360,共5页
Chinese Journal of Pharmacoepidemiology
基金
重庆市区域医学重点学科建设项目(编号:zdxk201606)。
